Moderna (MRNA -9.1%) is down, albeit on average volume, in apparent response to a decision from the USPTO’s Patent Trial and Appeal Board denying the company’s motion for an inter partes review of a patent (U.S. #8,058,069) held by Arbutus Biopharma (ABUS +80.9%) due to its failure to present sufficient evidence that the patent is unpatentable.
The ‘069 patent covers lipid formulations for nucleic acid delivery.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.